[go: up one dir, main page]

LV11183A - Jauns steroido organisko vielu kristalizacijas panemiens un ar to iegutie sastavi - Google Patents

Jauns steroido organisko vielu kristalizacijas panemiens un ar to iegutie sastavi

Info

Publication number
LV11183A
LV11183A LV950341A LV950341A LV11183A LV 11183 A LV11183 A LV 11183A LV 950341 A LV950341 A LV 950341A LV 950341 A LV950341 A LV 950341A LV 11183 A LV11183 A LV 11183A
Authority
LV
Latvia
Prior art keywords
pct
crystallization
organic matter
mixture
new strain
Prior art date
Application number
LV950341A
Other languages
English (en)
Other versions
LV11183B (en
Inventor
Michel Lanquetin
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Publication of LV11183A publication Critical patent/LV11183A/lv
Publication of LV11183B publication Critical patent/LV11183B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-95-341A 1990-11-12 1995-11-14 Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof LV11183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013981A FR2668945B1 (fr) 1990-11-12 1990-11-12 Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.

Publications (2)

Publication Number Publication Date
LV11183A true LV11183A (lv) 1996-04-20
LV11183B LV11183B (en) 1996-10-20

Family

ID=9402062

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-341A LV11183B (en) 1990-11-12 1995-11-14 Novel process for crystallising of substances of steroidal structure and pharmaceutical compositions containing thereof

Country Status (17)

Country Link
US (1) US5266712A (lv)
EP (1) EP0510167B1 (lv)
JP (1) JP3281954B2 (lv)
KR (1) KR100196895B1 (lv)
AT (1) ATE126806T1 (lv)
BR (1) BR9106012A (lv)
CA (1) CA2073760C (lv)
DE (1) DE69112379T2 (lv)
DK (1) DK0510167T3 (lv)
ES (1) ES2079172T3 (lv)
FI (1) FI111545B (lv)
FR (1) FR2668945B1 (lv)
GR (1) GR3018117T3 (lv)
HU (1) HU212780B (lv)
LV (1) LV11183B (lv)
RU (1) RU2126013C1 (lv)
WO (1) WO1992008730A1 (lv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US6432936B1 (en) * 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2002047693A2 (en) * 2000-12-14 2002-06-20 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products comprising a stabilizing agent in non-crystalline form
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
BRPI0414551B8 (pt) 2003-10-10 2021-05-25 Antares Pharma Ipl Ag formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20050192264A1 (en) * 2004-02-04 2005-09-01 Penfold Philip L. Slow release steroid composition
RU2253453C1 (ru) * 2004-03-15 2005-06-10 Общество с ограниченной ответственностью "ЮНАЛ" Противовоспалительная и антиаллергическая композиция
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US20090247569A1 (en) * 2006-08-03 2009-10-01 Claude Singer Process for Preparing Clopidogrel Bisulphate
CN101961311B (zh) * 2010-09-21 2012-11-21 中山大学 一种5α-雄甾(烷)-3β,5,6β-三醇注射剂及其制备方法
BR112014031914B1 (pt) * 2012-06-18 2021-12-14 Therapeuticsmd, Inc Formulação farmacêutica encapsulada para liberação intravaginal compreendendo estradiol e uso da mesma para o tratamento de atrofia vulvovaginal e de um sistoma associado, bem como de um estado urinário deficiente em estrogênio
CN112871079B (zh) * 2021-01-27 2023-05-16 丽江映华生物药业有限公司 醋酸诺美孕酮微粒的制备方法及制备装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) * 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2361847A (en) * 1937-09-04 1944-10-31 Schering Corp Aromatization of steroid compounds and more especially to the production of estrone-and estradiollike compounds and of their derivatives from delta 1, 2, 4, 5-androstadienol-17-one-3
US2897216A (en) * 1954-11-01 1959-07-28 Schering Corp Process for the preparation of steroidal dienes and intermediates obtained thereby
US3053865A (en) * 1958-03-19 1962-09-11 Merck & Co Inc Novel 16-alkyl and 16-alkylene steroids and processes
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3836628A (en) 1972-05-22 1974-09-17 Int Research & Dev Co Ltd Crystal growth modifier
DE2323812A1 (de) * 1973-05-11 1974-11-28 Jenapharm Veb Verfahren zur herstellung von kohlensaeurederivaten der oestranreihe
GB1515284A (en) * 1974-05-21 1978-06-21 Gastaud J Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
US4634694A (en) * 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4795747A (en) * 1985-12-23 1989-01-03 Latman Neal S 16-epiestriol to prevent, inhibit or reduce inflammation
US4956600A (en) * 1988-07-01 1990-09-11 Viteq Corporation High frequency current detector for a low frequency line

Also Published As

Publication number Publication date
DE69112379T2 (de) 1996-03-28
GR3018117T3 (en) 1996-02-29
EP0510167A1 (fr) 1992-10-28
EP0510167B1 (fr) 1995-08-23
FI111545B (fi) 2003-08-15
US5266712A (en) 1993-11-30
HU9202608D0 (en) 1992-10-28
ATE126806T1 (de) 1995-09-15
KR927003617A (ko) 1992-12-18
ES2079172T3 (es) 1996-01-01
FR2668945A1 (fr) 1992-05-15
JPH05503305A (ja) 1993-06-03
DE69112379D1 (de) 1995-09-28
CA2073760A1 (fr) 1992-05-13
JP3281954B2 (ja) 2002-05-13
HUT61319A (en) 1992-12-28
BR9106012A (pt) 1993-01-05
FR2668945B1 (fr) 1993-02-19
FI923188L (fi) 1992-07-10
CA2073760C (fr) 2003-09-23
HU212780B (en) 1996-11-28
FI923188A0 (fi) 1992-07-10
LV11183B (en) 1996-10-20
WO1992008730A1 (fr) 1992-05-29
KR100196895B1 (ko) 1999-06-15
DK0510167T3 (da) 1996-01-02
RU2126013C1 (ru) 1999-02-10

Similar Documents

Publication Publication Date Title
LV11183A (lv) Jauns steroido organisko vielu kristalizacijas panemiens un ar to iegutie sastavi
CO5011099A1 (es) Formulaciones en polvo en estado cristalino estable
KR870001431B1 (ko) 라니티딘 염산염의 제조방법
SK286488B6 (sk) Spôsob výroby polymorfnej formy I a II 17ß-(N-terc.butylkarbamoyl)-4-aza-5alfa-androst-1-en-3-onu
CA2086087A1 (en) Growth Hormone Crystals and a Process for Production of These GH-Crystals
KR900013950A (ko) (7α,17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온 화합물 및 약학적 담체를 함유한 약학적 조성물
EP0023594A1 (de) Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate
JPS6471816A (en) Pharmacologically useful polymetamorphosis of buspirone
FI82045C (fi) Foerfarande foer framstaellning av den terapeutiskt anvaendbara polymorf i-formen av monoetanolaminosaltet av n-(2-pyridyl)-2-metyl-4-hydroxi-2h-1,2-bensotiazin-3-karboamid-1,1 dioxid.
JPS5824595A (ja) ステロイド化合物およびその製造方法
CO4480032A1 (es) Cristales de glicosidos de espiroestanilo
US2566358A (en) Androgenic compositions
CA1064944A (en) Process for the preparation of n-(1-ethyl 2-pyrrolidyl methyl)-2-methoxy-5-sulfamoyl benzamide
WO1989007607A1 (en) 24r-scymnol, and preparation and use thereof
Yershov et al. Preparation of gallium arsenide films on insulators by artificial epitaxy
JPS5534115A (en) Crystallization method
JPS55104286A (en) Preparation of thienoimidazoline compound
JPS5616409A (en) Gamma-oryzanol pharmaceutical preparation
JPS549257A (en) Preparation of highly pure 1,8-dihydroanthraquinone
SU1737036A1 (ru) Способ извлечени монокристаллов YB @ С @ О @ из затвердевшего раствора-расплава
JPS61109770A (ja) ２位置にα‐ヒドロキシル鎖が置換した４‐ヒドロキシ‐３‐キノリンカルボン酸より誘導される新エステル、その製造、薬剤としての使用及びそれを含む組成物
Ishida et al. Preparation and Characterization of YBCO Superconducter Crystals by Laser Verneuil Method
Adams et al. 2, 4-and 4, 6-Dinitro-and Diamino-m-xylenes
DE2608697A1 (de) Neue organische verbindungen, ihre herstellung und verwendung
JPS5283750A (en) Crystals of 5-amino-4-imidazol-carboxyamide